TITLE

Long-term aspirin use decreased risk for multiple myeloma

PUB. DATE
March 2014
SOURCE
Hem/Onc Today;3/25/2014, Vol. 15 Issue 6, p19
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses a study by B. M. Birmann and colleagues published in a 2013 issue of "Cancer Prevention Research" about the association between the long-term use of aspirin and the decreased risk for multiple myeloma.
ACCESSION #
95441247

 

Related Articles

  • Continuous therapy with lenalidomide in multiple myeloma.  // British Journal of Hospital Medicine (17508460);Feb2010, Vol. 71 Issue 2, p70 

    The article reports on the study made by Dr. Antonio Palumbo of the University of Turin regarding the efficacy of Revlimid continuous therapy in treating multiple myeloma in Turin, Italy.

  • MULTIPLE MYELOMA MENACE. Karpa, Kelly Dowhower // Drug Topics;7/21/2003, Vol. 147 Issue 14, DRUG TOPICS FOR THE... p32 

    Focuses on the treatment of multiple myeloma. Pathophysiology; Drug categories.

  • Review of Revlimid highlights hepatotoxicity.  // Reactions Weekly;1/12/2013, Issue 1434, p2 

    The article reports on the severe cases of liver injury in patients receiving lenalidomide in combinaion with dexamethasone for the treatment of multiple myeloma, which was cited in the Celgene Pharmacovigilance database

  • Bortezomib.  // Reactions Weekly;10/1/2011, Issue 1371, p10 

    The article describes the case of seven patients who developed III-IV diarrhoea while being treated with bortezamib for multiple myeloma while others also experienced neuropathy and renal failure.

  • Bortezomib.  // Reactions Weekly;7/21/2012, Issue 1411, p12 

    The article describes the case of a man who developed acute cholestatic and parenchymal hepatitis and fatal liver after treatment with intravenous (IV) bortezomib for multiple myeloma.

  • Incl Myeloma Foundation Says Three Studies Highlighting Myeloma Treatment- Advances Are Featured Together in Prestigious New England Journal of Medicine.  // Biomedical Market Newsletter;5/12/2012, Vol. 21, p1 

    A correction to the publication of an article "The International Myeloma Foundation Says Three Studies Highlighting Myeloma Treatment-Advances are Featured Together in the Prestigious New England Journal of Medicine" is presented.

  • Sensitivity of multiple myeloma to imexon in the human tumor cloning assay. Salmon, Sydney E.; Hersh, Evan M. // JNCI: Journal of the National Cancer Institute;2/2/94, Vol. 86 Issue 3, p228 

    Reports on the sensitivity of multiple myeloma to imexon in the human tumor assay. Background information; Chemical structure of imexon; Mechanism of action.

  • Thalidomide for previously untreated indolent or smoldering multiple myeloma. Rajkumar, S V; Dispenzieri, A; Fonseca, R; Lacy, M Q; Geyer, S; Lust, J A; Kyle, R A; Greipp, P R; Gertz, M A; Witzig, T E // Leukemia (08876924);Aug2001, Vol. 15 Issue 8, p1274 

    We conducted a clinical trial of thalidomide as initial therapy for asymptomatic smoldering (SMM) or indolent multiple myeloma (IMM). Sixteen patients were studied. Thalidomide was given orally at a dose of 200 mg/day for 2 weeks, and then increased as tolerated by 200 mg/day every 2 weeks to a...

  • Thalidomide.  // Reactions Weekly;7/24/2010, Issue 1311, p40 

    The article describes the case of a man who developed peripheral neuropathy while receiving chemotherapy with thalidomide for multiple myeloma.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics